JP2016505613A - Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 - Google Patents

Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 Download PDF

Info

Publication number
JP2016505613A
JP2016505613A JP2015551250A JP2015551250A JP2016505613A JP 2016505613 A JP2016505613 A JP 2016505613A JP 2015551250 A JP2015551250 A JP 2015551250A JP 2015551250 A JP2015551250 A JP 2015551250A JP 2016505613 A JP2016505613 A JP 2016505613A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
months
oil
mcg
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015551250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505613A5 (enExample
Inventor
キドロン，ミリアム
アービット，エフド
Original Assignee
オラムド エルティーディー．
オラムド エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2013/050007 external-priority patent/WO2013102899A1/en
Application filed by オラムド エルティーディー．, オラムド エルティーディー． filed Critical オラムド エルティーディー．
Publication of JP2016505613A publication Critical patent/JP2016505613A/ja
Publication of JP2016505613A5 publication Critical patent/JP2016505613A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015551250A 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 Pending JP2016505613A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ILPCT/IL2013/050007 2013-01-03
PCT/IL2013/050007 WO2013102899A1 (en) 2012-01-03 2013-01-03 Methods and compositions for treating diabetes
US201361763996P 2013-02-13 2013-02-13
US61/763,996 2013-02-13
PCT/IL2014/050007 WO2014106846A2 (en) 2013-01-03 2014-01-02 Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018131875A Division JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2016505613A true JP2016505613A (ja) 2016-02-25
JP2016505613A5 JP2016505613A5 (enExample) 2017-01-05

Family

ID=51062529

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551250A Pending JP2016505613A (ja) 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2018131875A Pending JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2020102461A Pending JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2022156787A Pending JP2023002570A (ja) 2013-01-03 2022-09-29 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2025040577A Pending JP2025106279A (ja) 2013-01-03 2025-03-13 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018131875A Pending JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2020102461A Pending JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2022156787A Pending JP2023002570A (ja) 2013-01-03 2022-09-29 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2025040577A Pending JP2025106279A (ja) 2013-01-03 2025-03-13 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Country Status (5)

Country Link
US (4) US20150335715A1 (enExample)
EP (2) EP2941267B1 (enExample)
JP (5) JP2016505613A (enExample)
CN (2) CN110151979A (enExample)
WO (1) WO2014106846A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529566A (ja) * 2016-09-28 2019-10-17 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
WO2014142219A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 グアニジノ安息香酸エステル化合物
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3197913B1 (en) * 2014-09-22 2019-08-28 Hadasit Medical Research Services And Development Alpha-1 anti-trypsin for treating liver diseases
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
SG11202012340SA (en) * 2018-06-11 2021-01-28 Oramed Ltd Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
CN116251192A (zh) * 2020-01-16 2023-06-13 上海仁会生物制药股份有限公司 Glp-1给药方案

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006238886A (ja) * 1992-11-17 2006-09-14 E I Du Pont De Nemours & Co 変化したレベルの不飽和脂肪酸を含有する種子油およびその生産方法
JP2011515458A (ja) * 2008-03-26 2011-05-19 オラムド エルティーディー． タンパク質の経口投与方法及び組成物
JP2011519915A (ja) * 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
EP1414474A4 (en) 2001-07-18 2005-06-29 Solae Llc PROTEIN BOWMAN BIRK HEMMER CONCENTRATE AND MANUFACTURING METHOD THEREFOR
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
JP2010508262A (ja) 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
EP2144618B2 (en) 2007-03-28 2024-11-20 Aker Biomarine Antarctic As Bioeffective krill oil compositions
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009151125A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 肝障害の診断及び治療
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
TWI474835B (zh) * 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
EP2519251A4 (en) 2009-12-30 2013-08-28 Solae Llc ISOLATED CLEANED BOWMAN BIRK PROTEASE HEMMER PROTEINS FROM A SOYA PROCESSING STREAM
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
NZ603319A (en) * 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
ES2659763T3 (es) * 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
WO2013010289A1 (zh) 2011-07-15 2013-01-24 Chan Tu Cheng 填充式工件表面饰化方法
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2844269A4 (en) * 2012-03-28 2016-01-06 Amylin Pharmaceuticals Llc TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006238886A (ja) * 1992-11-17 2006-09-14 E I Du Pont De Nemours & Co 変化したレベルの不飽和脂肪酸を含有する種子油およびその生産方法
JP2011515458A (ja) * 2008-03-26 2011-05-19 オラムド エルティーディー． タンパク質の経口投与方法及び組成物
JP2011519915A (ja) * 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM, vol. 292, no. 3, JPN6018040512, 1 March 2007 (2007-03-01), pages 829 - 835, ISSN: 0003899288 *
MMR IN BIOMEDICINE, vol. 24, no. 7, JPN6018040514, August 2011 (2011-08-01), pages 784 - 790, ISSN: 0003899290 *
PLOS ONE[オンライン], vol. Volume 6, Issue 9, JPN6017033126, 11 September 2011 (2011-09-11), ISSN: 0003899286 *
日本内科学会雑誌, vol. 第１０１巻 第３号, JPN6018040513, 10 March 2012 (2012-03-10), pages 662 - 668, ISSN: 0003899289 *
日本栄養・食糧学会誌, vol. 第６４巻, 第２号, JPN6017033129, 2011, pages 91 - 98, ISSN: 0003899287 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529566A (ja) * 2016-09-28 2019-10-17 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
JP7022136B2 (ja) 2016-09-28 2022-02-17 アイガー・バイオファーマシューティカルズ・インコーポレイテッド 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
US11571403B2 (en) 2016-09-28 2023-02-07 Eiger Biopharmaceuticals, Inc. Methods for the treatment of non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
JP2018197240A (ja) 2018-12-13
JP2023002570A (ja) 2023-01-10
WO2014106846A3 (en) 2015-01-29
EP4215205A1 (en) 2023-07-26
EP2941267A2 (en) 2015-11-11
HK1217291A1 (en) 2017-01-06
US10967051B2 (en) 2021-04-06
EP2941267B1 (en) 2022-11-16
WO2014106846A2 (en) 2014-07-10
US20240181018A1 (en) 2024-06-06
EP2941267A4 (en) 2016-06-22
US20190209655A1 (en) 2019-07-11
JP2025106279A (ja) 2025-07-15
US20150335715A1 (en) 2015-11-26
US20220000986A1 (en) 2022-01-06
JP2020180126A (ja) 2020-11-05
CN110151979A (zh) 2019-08-23
CN104902921A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
US10967051B2 (en) Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof
US20230210956A1 (en) Methods and compositions for treating diabetes
RU2494755C2 (ru) Способы и композиции для перорального введения белков
JP7369033B2 (ja) 線維症の治療
ES2670856T3 (es) Métodos y composiciones para la administración oral de proteínas
JP6567827B2 (ja) プロテアーゼ阻害剤を含有する組成物、該組成物を含む組成物、および、該組成物を製造および使用する方法
KR20150127599A (ko) 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
US20180125862A1 (en) Treatment for hepatic fibrosis
WO2009118722A2 (en) Methods and compositions for oral administration of proteins
US20190175619A1 (en) Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
Farrugia et al. Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
HK1217291B (en) Compositions for use in treating nafld
Kurkin et al. Physiology and pharmacology of glucagon-like peptide-1 receptor
US20220362263A1 (en) Treatment for fibrosis and inhibition of fibrosis
US20250332176A1 (en) Treatment for fibrosis and inhibition of fibrosis
HK1203826B (en) Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
WO2018204918A1 (en) Treatment of hepatic disorders
CA3117958A1 (en) Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients
HK40029047A (en) Methods of treating chronic inflammatory diseases
BRPI0907077B1 (pt) Métodos e composições para administração oral de proteínas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180820

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190515